This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
|Articles|October 21, 2014
BioClean P-Zero™ - Excellent Cytotoxic Protection
Part of the BioClean Chemo Safety Wear range BioClean P-Zero? sterile cleanroom gloves are made from polychloroprene, provide exceptional cytotoxic protection, are antistatic and have outstanding tactility and grip.
Advertisement
BioClean P-Zero™ - Excellent Cytotoxic Protection
BioClean P-Zero™ (BPZS) sterile gloves provide exceptional cytotoxic protection, are antistatic and have outstanding tactility and grip.
The BioClean™ Chemo Safety Wear range, the P-Zero are hand-specific 300mm (12”) latex-free, powder-free, natural-coloured gloves featuring a textured surface and beaded cuff for strength and stability on the wrist. Packed in a non-particulating EasyTear™ pouch, they are ISO Class 4 and EU GMP Grade A compatible and available in sizes 6.0 to 9.0 (including half sizes.)
All BioClean Chemo Safety Wear gloves are tested against the most stringent standard ASTM D6978-05 (standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs) which is 100 times more stringent than its European counterpart EN 374-3:2003, meaning BioClean P-Zero gloves are the safe choice to make.
Contact Details:
Nitritex Ltd
Minton Enterprise Park, Oaks Drive
Newmarket, Suffolk, CB8 7YY
Advertisement
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Advertisement
Advertisement